Histamine receptor antagonists and incident colorectal adenomas

D. J. Robertson, C. A. Burke, B. J. Schwender, Michael J Wargovich, E. R. Greenberg, R. S. Sandler, D. J. Ahnen, R. Rothstein, L. A. Mott, J. A. Baron

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Prior studies suggest that histamines may modulate the development of colorectal neoplasia. Aim: To assess whether histamine receptor antagonist use was associated with adenoma formation. Methods: Patients (n = 2366) were drawn from three adenoma chemoprevention trials. All underwent baseline colonoscopy with removal of adenoma(s) and were deemed free of remaining lesions; they were followed with surveillance colonoscopy. Medication use was assessed by questionnaire. Adjusted risk ratios for adenoma formation related to histamine receptor antagonist use (histamine H1 and H2 receptor, H1RA and H2RA) were determined using log linear models. Results: In pooled analyses, H1RA exposure was not associated with subsequent adenoma risk (RR = 1.10; 95% CI 0.97-1.25) or multiple adenoma formation (RR = 0.85; 95% CI 0.67-1.07). H2RA use also was not associated with adenoma (RR = 0.90; 95% CI 0.77-1.06), or multiple adenoma (RR = 0.77; 95% CI 0.57-1.04) in the pooled analyses, but H2RA users in the first trial had a decreased risk of adenoma (RR = 0.70; 95% CI 0.48-1.03) and multiple adenoma (RR = 0.31; 95% CI 0.12-0.79). Conclusion: H2RA use was associated with reduced risk for adenoma in one trial, but not in the pooled analyses. Further study would be warranted before undertaking randomized trials of H2RAs for adenoma chemoprevention.

Original languageEnglish (US)
Pages (from-to)123-128
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Volume22
Issue number2
DOIs
StatePublished - Jul 15 2005
Externally publishedYes

Fingerprint

Histamine Receptors
Histamine Antagonists
Adenoma
Chemoprevention
Colonoscopy
Histamine H1 Receptors
Histamine H2 Receptors
Histamine
Linear Models

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Robertson, D. J., Burke, C. A., Schwender, B. J., Wargovich, M. J., Greenberg, E. R., Sandler, R. S., ... Baron, J. A. (2005). Histamine receptor antagonists and incident colorectal adenomas. Alimentary Pharmacology and Therapeutics, 22(2), 123-128. https://doi.org/10.1111/j.1365-2036.2005.02529.x

Histamine receptor antagonists and incident colorectal adenomas. / Robertson, D. J.; Burke, C. A.; Schwender, B. J.; Wargovich, Michael J; Greenberg, E. R.; Sandler, R. S.; Ahnen, D. J.; Rothstein, R.; Mott, L. A.; Baron, J. A.

In: Alimentary Pharmacology and Therapeutics, Vol. 22, No. 2, 15.07.2005, p. 123-128.

Research output: Contribution to journalArticle

Robertson, DJ, Burke, CA, Schwender, BJ, Wargovich, MJ, Greenberg, ER, Sandler, RS, Ahnen, DJ, Rothstein, R, Mott, LA & Baron, JA 2005, 'Histamine receptor antagonists and incident colorectal adenomas', Alimentary Pharmacology and Therapeutics, vol. 22, no. 2, pp. 123-128. https://doi.org/10.1111/j.1365-2036.2005.02529.x
Robertson, D. J. ; Burke, C. A. ; Schwender, B. J. ; Wargovich, Michael J ; Greenberg, E. R. ; Sandler, R. S. ; Ahnen, D. J. ; Rothstein, R. ; Mott, L. A. ; Baron, J. A. / Histamine receptor antagonists and incident colorectal adenomas. In: Alimentary Pharmacology and Therapeutics. 2005 ; Vol. 22, No. 2. pp. 123-128.
@article{e9e32aea8bd946bfa972c0a9211e3bcd,
title = "Histamine receptor antagonists and incident colorectal adenomas",
abstract = "Background: Prior studies suggest that histamines may modulate the development of colorectal neoplasia. Aim: To assess whether histamine receptor antagonist use was associated with adenoma formation. Methods: Patients (n = 2366) were drawn from three adenoma chemoprevention trials. All underwent baseline colonoscopy with removal of adenoma(s) and were deemed free of remaining lesions; they were followed with surveillance colonoscopy. Medication use was assessed by questionnaire. Adjusted risk ratios for adenoma formation related to histamine receptor antagonist use (histamine H1 and H2 receptor, H1RA and H2RA) were determined using log linear models. Results: In pooled analyses, H1RA exposure was not associated with subsequent adenoma risk (RR = 1.10; 95{\%} CI 0.97-1.25) or multiple adenoma formation (RR = 0.85; 95{\%} CI 0.67-1.07). H2RA use also was not associated with adenoma (RR = 0.90; 95{\%} CI 0.77-1.06), or multiple adenoma (RR = 0.77; 95{\%} CI 0.57-1.04) in the pooled analyses, but H2RA users in the first trial had a decreased risk of adenoma (RR = 0.70; 95{\%} CI 0.48-1.03) and multiple adenoma (RR = 0.31; 95{\%} CI 0.12-0.79). Conclusion: H2RA use was associated with reduced risk for adenoma in one trial, but not in the pooled analyses. Further study would be warranted before undertaking randomized trials of H2RAs for adenoma chemoprevention.",
author = "Robertson, {D. J.} and Burke, {C. A.} and Schwender, {B. J.} and Wargovich, {Michael J} and Greenberg, {E. R.} and Sandler, {R. S.} and Ahnen, {D. J.} and R. Rothstein and Mott, {L. A.} and Baron, {J. A.}",
year = "2005",
month = "7",
day = "15",
doi = "10.1111/j.1365-2036.2005.02529.x",
language = "English (US)",
volume = "22",
pages = "123--128",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Histamine receptor antagonists and incident colorectal adenomas

AU - Robertson, D. J.

AU - Burke, C. A.

AU - Schwender, B. J.

AU - Wargovich, Michael J

AU - Greenberg, E. R.

AU - Sandler, R. S.

AU - Ahnen, D. J.

AU - Rothstein, R.

AU - Mott, L. A.

AU - Baron, J. A.

PY - 2005/7/15

Y1 - 2005/7/15

N2 - Background: Prior studies suggest that histamines may modulate the development of colorectal neoplasia. Aim: To assess whether histamine receptor antagonist use was associated with adenoma formation. Methods: Patients (n = 2366) were drawn from three adenoma chemoprevention trials. All underwent baseline colonoscopy with removal of adenoma(s) and were deemed free of remaining lesions; they were followed with surveillance colonoscopy. Medication use was assessed by questionnaire. Adjusted risk ratios for adenoma formation related to histamine receptor antagonist use (histamine H1 and H2 receptor, H1RA and H2RA) were determined using log linear models. Results: In pooled analyses, H1RA exposure was not associated with subsequent adenoma risk (RR = 1.10; 95% CI 0.97-1.25) or multiple adenoma formation (RR = 0.85; 95% CI 0.67-1.07). H2RA use also was not associated with adenoma (RR = 0.90; 95% CI 0.77-1.06), or multiple adenoma (RR = 0.77; 95% CI 0.57-1.04) in the pooled analyses, but H2RA users in the first trial had a decreased risk of adenoma (RR = 0.70; 95% CI 0.48-1.03) and multiple adenoma (RR = 0.31; 95% CI 0.12-0.79). Conclusion: H2RA use was associated with reduced risk for adenoma in one trial, but not in the pooled analyses. Further study would be warranted before undertaking randomized trials of H2RAs for adenoma chemoprevention.

AB - Background: Prior studies suggest that histamines may modulate the development of colorectal neoplasia. Aim: To assess whether histamine receptor antagonist use was associated with adenoma formation. Methods: Patients (n = 2366) were drawn from three adenoma chemoprevention trials. All underwent baseline colonoscopy with removal of adenoma(s) and were deemed free of remaining lesions; they were followed with surveillance colonoscopy. Medication use was assessed by questionnaire. Adjusted risk ratios for adenoma formation related to histamine receptor antagonist use (histamine H1 and H2 receptor, H1RA and H2RA) were determined using log linear models. Results: In pooled analyses, H1RA exposure was not associated with subsequent adenoma risk (RR = 1.10; 95% CI 0.97-1.25) or multiple adenoma formation (RR = 0.85; 95% CI 0.67-1.07). H2RA use also was not associated with adenoma (RR = 0.90; 95% CI 0.77-1.06), or multiple adenoma (RR = 0.77; 95% CI 0.57-1.04) in the pooled analyses, but H2RA users in the first trial had a decreased risk of adenoma (RR = 0.70; 95% CI 0.48-1.03) and multiple adenoma (RR = 0.31; 95% CI 0.12-0.79). Conclusion: H2RA use was associated with reduced risk for adenoma in one trial, but not in the pooled analyses. Further study would be warranted before undertaking randomized trials of H2RAs for adenoma chemoprevention.

UR - http://www.scopus.com/inward/record.url?scp=22844436210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22844436210&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2005.02529.x

DO - 10.1111/j.1365-2036.2005.02529.x

M3 - Article

VL - 22

SP - 123

EP - 128

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -